1 day Ago By Paul Lee
LEESOL, a healthcare startup operating an electronic drug platform for the prevention, diagnosis, and treatment of brain diseases, has announced the successful acquisition of 4 billion won in Series A funding from venture capital firms and pharmaceutical companies, including ViNe Ventures and Kolon Pharmaceutical. Founded in October 2017 by Dr. Lee Seung-woo, cofounder of Medison, a first-generation medical device company, and Kwon Gu-seong, a patent attorney, LEESOL aims to provide healthy brain solutions for mental disorders such as sleep disorders and depression, as well as degenerative brain diseases like Alzheimer’s disease.
ViNe Ventures participated as the anchor investor, contributing 1.5 billion won, while Kolon Pharmaceutical, Korea Alternative Investment Asset Management, New Paradigm Investment, and FIND US also joined the funding round. Notably, Kolon Pharmaceutical participated as a strategic investor in this funding round, focusing on electronic drugs related to depression, while New Paradigm Investment acted as a follow-up investor after its initial pre-Series A investment.
Recently, LEESOL was selected for the Ministry of SMEs and Startups’ Deep Tech TIPS program, securing up to 1.7 billion won in research and development funds. The company has also received 1.
1 billion won in R&D support as part of the Ministry of Health and Welfare's health technology research and development project focused on electronic drug technology..
